Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM): Results of the feasibility trial

Carlos Abraira, John A. Colwell, Frank Q. Nuttall, Clark T. Sawin, Nancy Johnson Nagel, John P. Comstock, Nicholas V. Emanuele, Seymour R. Levin, William Henderson, Hae Sook Lee

Research output: Contribution to journalArticle

362 Citations (Scopus)

Abstract

OBJECTIVE - It is not clear whether intensive pharmacologic therapy can be effectively sustained in non-insulin-dependent diabetes mellitus (NIDDM). The relative risks and benefits of intensive insulin therapy in NIDDM are not well defined. Accordingly, we designed a feasibility study that compared standard therapy and intensive therapy in a group of NIDDM men who required insulin due to sustained hyperglycemia. RESEARCH DESIGN AND METHODS - A prospective trial was conducted in five medical centers in 153 men of 60 ± 6 years of age who had a known diagnosis of diabetes for 7.8 ± 4 years. They were randomly assigned to a standard insulin treatment group (one morning injection per day) or to an intensive therapy group designed to attain near- normal glycemia and a clinically significant separation of glycohemoglobin from the standard arm. A four-step plan was used in the intensive therapy group along with daily self-monitoring of glucose; 1) an evening insulin injection, 2) the same injection adding daytime glipizide, 3) two injections of insulin alone, and 4) multiple daily injections. Patient accrual and adherence, glycohemoglobin (HbA(1c)), side effects, and measurements of endpoints for a prospective long-term trial were assessed. RESULTS - Accrual goals were met, mean follow-up time was 27 months (range 18-35 months), and patients kept 98.6% of scheduled visits. After 6 months, the mean Hba(1c), in the intensive therapy group was at or below 7.3% and remained 2% lower than the standard group for the duration of the trial. Most of the decrease in the mean HbA(1c) in the intensive group was obtained by a single injection of evening intermediate insulin, alone or with daytime glipizide. By the end of the trial, 64% of the patients had advanced to two or more injections of insulin a day, aiming for normal HbA1c. However, only a small additional fall in HbA(1c) was attained. Severe hypoglycemia was rare (two events per 100 patients per year) and not significantly different between the groups, nor were changes in weight, blood pressure, or plasma lipids. There were 61 new cardiovascular events in 40 patients and 10 deaths (6 due to cardiovascular causes). CONCLUSIONS - Intense steeped insulin therapy in NIDDM patients who have failed glycemic control on pharmacological therapy is effective in maintaining near-normal glycemic control for >2 years without excessive severe hypoglycemia, weight gain, hypertension, or dyslipidemia. Cardiovascular event rates are high at this stage of NIDDM. A long-term prospective trial is needed to assess the risk-benefit ratio of intensified treatment of hyperglycemia in NIDDM patients requiring insulin.

Original languageEnglish
Pages (from-to)1113-1123
Number of pages11
JournalDiabetes Care
Volume18
Issue number8
StatePublished - Aug 1 1995

Fingerprint

Veterans
Type 2 Diabetes Mellitus
Insulin
Injections
Group Psychotherapy
Glipizide
Therapeutics
Hypoglycemia
Hyperglycemia
Feasibility Studies
Patient Compliance
Dyslipidemias
Weight Gain
Research Design
Odds Ratio
Pharmacology
Blood Pressure
Hypertension
Lipids
Weights and Measures

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Abraira, C., Colwell, J. A., Nuttall, F. Q., Sawin, C. T., Nagel, N. J., Comstock, J. P., ... Lee, H. S. (1995). Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM): Results of the feasibility trial. Diabetes Care, 18(8), 1113-1123.

Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM) : Results of the feasibility trial. / Abraira, Carlos; Colwell, John A.; Nuttall, Frank Q.; Sawin, Clark T.; Nagel, Nancy Johnson; Comstock, John P.; Emanuele, Nicholas V.; Levin, Seymour R.; Henderson, William; Lee, Hae Sook.

In: Diabetes Care, Vol. 18, No. 8, 01.08.1995, p. 1113-1123.

Research output: Contribution to journalArticle

Abraira, C, Colwell, JA, Nuttall, FQ, Sawin, CT, Nagel, NJ, Comstock, JP, Emanuele, NV, Levin, SR, Henderson, W & Lee, HS 1995, 'Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM): Results of the feasibility trial', Diabetes Care, vol. 18, no. 8, pp. 1113-1123.
Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM): Results of the feasibility trial. Diabetes Care. 1995 Aug 1;18(8):1113-1123.
Abraira, Carlos ; Colwell, John A. ; Nuttall, Frank Q. ; Sawin, Clark T. ; Nagel, Nancy Johnson ; Comstock, John P. ; Emanuele, Nicholas V. ; Levin, Seymour R. ; Henderson, William ; Lee, Hae Sook. / Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM) : Results of the feasibility trial. In: Diabetes Care. 1995 ; Vol. 18, No. 8. pp. 1113-1123.
@article{02e05e245649459b891e18896b329eb4,
title = "Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM): Results of the feasibility trial",
abstract = "OBJECTIVE - It is not clear whether intensive pharmacologic therapy can be effectively sustained in non-insulin-dependent diabetes mellitus (NIDDM). The relative risks and benefits of intensive insulin therapy in NIDDM are not well defined. Accordingly, we designed a feasibility study that compared standard therapy and intensive therapy in a group of NIDDM men who required insulin due to sustained hyperglycemia. RESEARCH DESIGN AND METHODS - A prospective trial was conducted in five medical centers in 153 men of 60 ± 6 years of age who had a known diagnosis of diabetes for 7.8 ± 4 years. They were randomly assigned to a standard insulin treatment group (one morning injection per day) or to an intensive therapy group designed to attain near- normal glycemia and a clinically significant separation of glycohemoglobin from the standard arm. A four-step plan was used in the intensive therapy group along with daily self-monitoring of glucose; 1) an evening insulin injection, 2) the same injection adding daytime glipizide, 3) two injections of insulin alone, and 4) multiple daily injections. Patient accrual and adherence, glycohemoglobin (HbA(1c)), side effects, and measurements of endpoints for a prospective long-term trial were assessed. RESULTS - Accrual goals were met, mean follow-up time was 27 months (range 18-35 months), and patients kept 98.6{\%} of scheduled visits. After 6 months, the mean Hba(1c), in the intensive therapy group was at or below 7.3{\%} and remained 2{\%} lower than the standard group for the duration of the trial. Most of the decrease in the mean HbA(1c) in the intensive group was obtained by a single injection of evening intermediate insulin, alone or with daytime glipizide. By the end of the trial, 64{\%} of the patients had advanced to two or more injections of insulin a day, aiming for normal HbA1c. However, only a small additional fall in HbA(1c) was attained. Severe hypoglycemia was rare (two events per 100 patients per year) and not significantly different between the groups, nor were changes in weight, blood pressure, or plasma lipids. There were 61 new cardiovascular events in 40 patients and 10 deaths (6 due to cardiovascular causes). CONCLUSIONS - Intense steeped insulin therapy in NIDDM patients who have failed glycemic control on pharmacological therapy is effective in maintaining near-normal glycemic control for >2 years without excessive severe hypoglycemia, weight gain, hypertension, or dyslipidemia. Cardiovascular event rates are high at this stage of NIDDM. A long-term prospective trial is needed to assess the risk-benefit ratio of intensified treatment of hyperglycemia in NIDDM patients requiring insulin.",
author = "Carlos Abraira and Colwell, {John A.} and Nuttall, {Frank Q.} and Sawin, {Clark T.} and Nagel, {Nancy Johnson} and Comstock, {John P.} and Emanuele, {Nicholas V.} and Levin, {Seymour R.} and William Henderson and Lee, {Hae Sook}",
year = "1995",
month = "8",
day = "1",
language = "English",
volume = "18",
pages = "1113--1123",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "8",

}

TY - JOUR

T1 - Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM)

T2 - Results of the feasibility trial

AU - Abraira, Carlos

AU - Colwell, John A.

AU - Nuttall, Frank Q.

AU - Sawin, Clark T.

AU - Nagel, Nancy Johnson

AU - Comstock, John P.

AU - Emanuele, Nicholas V.

AU - Levin, Seymour R.

AU - Henderson, William

AU - Lee, Hae Sook

PY - 1995/8/1

Y1 - 1995/8/1

N2 - OBJECTIVE - It is not clear whether intensive pharmacologic therapy can be effectively sustained in non-insulin-dependent diabetes mellitus (NIDDM). The relative risks and benefits of intensive insulin therapy in NIDDM are not well defined. Accordingly, we designed a feasibility study that compared standard therapy and intensive therapy in a group of NIDDM men who required insulin due to sustained hyperglycemia. RESEARCH DESIGN AND METHODS - A prospective trial was conducted in five medical centers in 153 men of 60 ± 6 years of age who had a known diagnosis of diabetes for 7.8 ± 4 years. They were randomly assigned to a standard insulin treatment group (one morning injection per day) or to an intensive therapy group designed to attain near- normal glycemia and a clinically significant separation of glycohemoglobin from the standard arm. A four-step plan was used in the intensive therapy group along with daily self-monitoring of glucose; 1) an evening insulin injection, 2) the same injection adding daytime glipizide, 3) two injections of insulin alone, and 4) multiple daily injections. Patient accrual and adherence, glycohemoglobin (HbA(1c)), side effects, and measurements of endpoints for a prospective long-term trial were assessed. RESULTS - Accrual goals were met, mean follow-up time was 27 months (range 18-35 months), and patients kept 98.6% of scheduled visits. After 6 months, the mean Hba(1c), in the intensive therapy group was at or below 7.3% and remained 2% lower than the standard group for the duration of the trial. Most of the decrease in the mean HbA(1c) in the intensive group was obtained by a single injection of evening intermediate insulin, alone or with daytime glipizide. By the end of the trial, 64% of the patients had advanced to two or more injections of insulin a day, aiming for normal HbA1c. However, only a small additional fall in HbA(1c) was attained. Severe hypoglycemia was rare (two events per 100 patients per year) and not significantly different between the groups, nor were changes in weight, blood pressure, or plasma lipids. There were 61 new cardiovascular events in 40 patients and 10 deaths (6 due to cardiovascular causes). CONCLUSIONS - Intense steeped insulin therapy in NIDDM patients who have failed glycemic control on pharmacological therapy is effective in maintaining near-normal glycemic control for >2 years without excessive severe hypoglycemia, weight gain, hypertension, or dyslipidemia. Cardiovascular event rates are high at this stage of NIDDM. A long-term prospective trial is needed to assess the risk-benefit ratio of intensified treatment of hyperglycemia in NIDDM patients requiring insulin.

AB - OBJECTIVE - It is not clear whether intensive pharmacologic therapy can be effectively sustained in non-insulin-dependent diabetes mellitus (NIDDM). The relative risks and benefits of intensive insulin therapy in NIDDM are not well defined. Accordingly, we designed a feasibility study that compared standard therapy and intensive therapy in a group of NIDDM men who required insulin due to sustained hyperglycemia. RESEARCH DESIGN AND METHODS - A prospective trial was conducted in five medical centers in 153 men of 60 ± 6 years of age who had a known diagnosis of diabetes for 7.8 ± 4 years. They were randomly assigned to a standard insulin treatment group (one morning injection per day) or to an intensive therapy group designed to attain near- normal glycemia and a clinically significant separation of glycohemoglobin from the standard arm. A four-step plan was used in the intensive therapy group along with daily self-monitoring of glucose; 1) an evening insulin injection, 2) the same injection adding daytime glipizide, 3) two injections of insulin alone, and 4) multiple daily injections. Patient accrual and adherence, glycohemoglobin (HbA(1c)), side effects, and measurements of endpoints for a prospective long-term trial were assessed. RESULTS - Accrual goals were met, mean follow-up time was 27 months (range 18-35 months), and patients kept 98.6% of scheduled visits. After 6 months, the mean Hba(1c), in the intensive therapy group was at or below 7.3% and remained 2% lower than the standard group for the duration of the trial. Most of the decrease in the mean HbA(1c) in the intensive group was obtained by a single injection of evening intermediate insulin, alone or with daytime glipizide. By the end of the trial, 64% of the patients had advanced to two or more injections of insulin a day, aiming for normal HbA1c. However, only a small additional fall in HbA(1c) was attained. Severe hypoglycemia was rare (two events per 100 patients per year) and not significantly different between the groups, nor were changes in weight, blood pressure, or plasma lipids. There were 61 new cardiovascular events in 40 patients and 10 deaths (6 due to cardiovascular causes). CONCLUSIONS - Intense steeped insulin therapy in NIDDM patients who have failed glycemic control on pharmacological therapy is effective in maintaining near-normal glycemic control for >2 years without excessive severe hypoglycemia, weight gain, hypertension, or dyslipidemia. Cardiovascular event rates are high at this stage of NIDDM. A long-term prospective trial is needed to assess the risk-benefit ratio of intensified treatment of hyperglycemia in NIDDM patients requiring insulin.

UR - http://www.scopus.com/inward/record.url?scp=0029082033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029082033&partnerID=8YFLogxK

M3 - Article

C2 - 7587846

AN - SCOPUS:0029082033

VL - 18

SP - 1113

EP - 1123

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 8

ER -